Aclaris Therapeutics (ACRS) Operating Income: 2017-2025
Historic Operating Income for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to -$17.1 million.
- Aclaris Therapeutics' Operating Income fell 63.78% to -$17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$153.3 million, marking a year-over-year decrease of 231.11%. This contributed to the annual value of -$141.9 million for FY2024, which is 45.79% down from last year.
- Aclaris Therapeutics' Operating Income amounted to -$17.1 million in Q3 2025, which was up 6.84% from -$18.4 million recorded in Q2 2025.
- In the past 5 years, Aclaris Therapeutics' Operating Income registered a high of -$4.0 million during Q4 2023, and its lowest value of -$99.7 million during Q4 2024.
- Moreover, its 3-year median value for Operating Income was -$18.4 million (2025), whereas its average is -$26.6 million.
- Per our database at Business Quant, Aclaris Therapeutics' Operating Income skyrocketed by 86.08% in 2023 and then crashed by 2,362.94% in 2024.
- Aclaris Therapeutics' Operating Income (Quarterly) stood at -$22.9 million in 2021, then dropped by 27.02% to -$29.1 million in 2022, then skyrocketed by 86.08% to -$4.0 million in 2023, then slumped by 2,362.94% to -$99.7 million in 2024, then plummeted by 63.78% to -$17.1 million in 2025.
- Its Operating Income stands at -$17.1 million for Q3 2025, versus -$18.4 million for Q2 2025 and -$18.1 million for Q1 2025.